Michael Tomsicek

Mr. Tomsicek is CFO of Crispr Therapeutics and brings over 20 years of corporate and financial leadership experience to Milestone. Prior to joining CRISPR, he served as the Chief Financial Officer of Abiomed, a leading medical device company developing and commercializing products to aid in circulatory support. Mr. Tomsicek has also served as Chief Financial Officer at Cubist Pharmaceuticals, where he held various roles in financial operations, investor relations, and corporate strategy. During his tenure at Cubist, Mr. Tomsicek also saw the transition as the company was acquired by Merck. Mr. Tomsicek also served in a series of financial leadership positions at General Electric Healthcare, where he oversaw the global ultrasound business.

Mr. Tomsicek obtained an MBA and a BS in Engineering, both from the University of Wisconsin.